April 8, 2022Beijing Beilu Pharmaceutical Co., Ltd. (300016) announced today that Gadobutrol injection has obtained the "Drug Registration Certificate" issued by the NMPA(National Medial Production Administr...view
June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view
November 1, 2024Recently, Beijing Beilu Pharmaceutical Co., Ltd.'s contrast agent production linepassed the GMP (Good Manufacturing Practice) certification by Brazil's National Health Surveillance Agency (ANV...view
July 11, 2024Recently, the Beijing Municipal Drug Administration and the Beijing Municipal Health Commission released a "Notification on Units and Individuals with Outstanding Performance in Drug, Medical Dev...view
December 2, 2021To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...view